Spondyloarthritis & psoriatic arthritis
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
Authors' conclusion
Bimekizumab treatment led to early improvements in physical function, sleep, work productivity and overall HRQoL at Week 16 in patients across the full axSpA disease spectrum. Improvements were sustained to Week 52.
Study context
- Population
- Patients with nr-axSpA and r-axSpA
- Comparison
- Bimekizumab 160 mg SC every 4 weeks vs placebo
Methodological detailsphase 3, placebo-controlled to Week 16, all patients received bimekizumab from Week 16
- Phase 3
- Placebo-controlled to Week 16
- All patients received bimekizumab from Week 16
Primary result
As reported in the abstract
Physical functioning, sleep, work productivity and health-related quality of life (HRQoL) (BASFI, MOS-Sleep-R Index II, WPAI:axSpA, SF-36 PCS/MCS, ASQoL) · Week 16
- Significantly greater improvement from baseline vs placebo in Bath Ankylosing Spondylitis Functional Index (BASFI), SF-36 PCS and Ankylosing Spondylitis Quality of Life (ASQoL)
- p<0.001
Further findings
BASFI ≤4 and meaningful improvements in SF-36 PCS and ASQoL in bimekizumab-treated patients · Week 52
- Responses sustained or further improved; achieved by bimekizumab-treated patients regardless of original randomisation
- 60%-70%
Original publication
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies. RMD Open. Published 4 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →